Walgreens (WBA) was the worst-performing stock in the S&P 500 (^GSPC) in 2024. The stock surged though after the ...

For the last six to seven weeks, Gland Pharma stock has witnessed a series of consolidations as prices fluctuated in the range of 1700-1850 levels. It broke out from the said range last week. Traders ...

Stockhead’s Fraser Palamara sits down with Island Pharmaceuticals (ASX:ILA)  CEO and managing director David Foster to get the short end of the long story on the company’s latest news.

The stock market journey in 2024 was a rollercoaster, with an exceptional rally in the first half, followed by a sharp correction in the latter half. Despite the volatility, the Nifty closed the year ...

This week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate ...

Boobalan Pachaiyappan, an analyst from Roth MKM, has initiated a new Buy rating on Verona Pharma (VRNA).Stay Ahead of the Market:Discover ...

We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at ...

Vanda Pharmaceuticals Inc. VNDA generates revenues ... investor focus remains on the VNDA stock. Some other top-ranked stocks from the biotech sector are Puma Biotechnology, Inc. PBYI and Castle ...

Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with ...

Alnylam's TTR franchise, powered by Amvuttra, poised for $7.5B peak revenue with undervalued shares and long-term growth ...

Avadel Pharmaceuticals reported revenue targets for its narcolepsy treatment Lumryz that missed analyst estimates. The company said it expects net product revenue to be $240 million to $260 million in ...